期刊
PEDIATRIC BLOOD & CANCER
卷 70, 期 9, 页码 -出版社
WILEY
DOI: 10.1002/pbc.30481
关键词
gray zone lymphoma; mediastinum; pediatrics; WHO classification
The 2022 WHO classification redefines gray zone lymphoma (GZL) and restricts it to mediastinal origin cases called mediastinal gray zone lymphoma (MGZL) with overlapping features between primary mediastinal B-cell lymphoma (PMBCL) and classical Hodgkin lymphoma (CHL). Cases without mediastinal involvement are better classified as diffuse large B-cell lymphoma, not otherwise specified (DLBCL NOS). Clinical and pathological data of Italian pediatric patients with GZL were collected over a 20-year period. Only four cases of bona fide MGZL were identified, showing a more aggressive clinical behavior than PMBCL or CHL. Prospective studies are needed to evaluate prognostic factors and establish the most effective first-line therapy for MGZL.
BackgroundThe 2022 World Health Organization (WHO) classification redefines the concept of gray zone lymphoma (GZL), restricting it in practice to cases of mediastinal/thymic origin (mediastinal gray zone lymphoma, MGZL) with overlapping features between primary mediastinal B-cell lymphoma (PMBCL) and classical Hodgkin lymphoma (CHL). Cases with histological characteristics of GZL but occurring without mediastinal involvement are better classified as diffuse large B-cell lymphoma, not otherwise specified (DLBCL NOS), with few exceptions. ProcedureWe collected clinical and pathological data about all Italian pediatric patients diagnosed with GZL over a 20-year period. ResultsWe identified only four cases of bona fide MGZL. All patients were adolescent and presented with a mediastinal disease, always associated with other nodal involvement. B symptoms and increased levels of both erythrocyte sedimentation rate (ESR) and lactate dehydrogenase (LDH) were observed. Only two patients achieved a first complete remission, suggesting a more aggressive clinical behavior than either PMBCL or CHL. ConclusionProspective studies evaluating prognostic factors and establishing the most effective first-line therapy for MGZL are highly needed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据